RT Journal Article
SR Electronic
T1 Identification of a de novo mutation in TLK1 associated with a neurodevelopmental disorder and immunodeficiency
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.08.22.23294267
DO 10.1101/2023.08.22.23294267
A1 Villamor-Payà, Marina
A1 Sanchiz-Calvo, María
A1 Smak, Jordann
A1 Pais, Lynn
A1 Sud, Malika
A1 Shankavaram, Uma
A1 Lovgren, Alysia Kern
A1 Austin-Tse, Christina
A1 Ganesh, Vijay S
A1 Gay, Marina
A1 Vilaseca, Marta
A1 Arauz-Garofalo, Gianluca
A1 Palenzuela, Lluís
A1 VanNoy, Grace
A1 O’Donnell-Luria, Anne
A1 Stracker, Travis H.
YR 2023
UL http://medrxiv.org/content/early/2023/08/24/2023.08.22.23294267.abstract
AB Background The Tousled-like kinases 1 and 2 (TLK1/TLK2) regulate DNA replication, repair and chromatin maintenance. TLK2 variants are associated with ‘Intellectual Disability, Autosomal Dominant 57’ (MRD57), a neurodevelopmental disorder (NDD) characterized by intellectual disability (ID), autism spectrum disorder (ASD) and microcephaly. Several TLK1 variants have been reported in NDDs but their functional significance is unknown.Methods A male patient presenting with ID, seizures, global developmental delay, hypothyroidism, and primary immunodeficiency was determined to have a novel, heterozygous variant in TLK1 (c.1435C>G, p.Q479E) by genome sequencing (GS). Single cell gel electrophoresis, western blot, flow cytometry and RNA-seq were performed in patient-derived lymphoblast cell lines. In silico, biochemical and proteomic analysis were used to determine the functional impact of the p.Q479E variant and previously reported NDD-associated TLK1 variant, p.M566T.Results Transcriptome sequencing in patient-derived cells confirmed expression of TLK1 transcripts carrying the p.Q479E variant and revealed alterations in genes involved in class switch recombination and cytokine signaling. Cells expressing the p.Q479E variant exhibited reduced cytokine responses and higher levels of spontaneous DNA damage but not increased sensitivity to radiation or DNA repair defects. The p.Q479E and p.M566T variants impaired kinase activity but did not strongly alter localization or proximal protein interactions.Conclusion Our study provides the first functional characterization of TLK1 variants associated with NDDs and suggests potential involvement in central nervous system and immune system development. Our results indicate that, like TLK2 variants, TLK1 variants may impact development in multiple tissues and should be considered in the diagnosis of rare NDDs.Competing Interest StatementThe authors have declared no competing interest.Funding StatementM.V-P. was funded by an FPI fellowship from the Ministry of Science, Innovation and Universities (MCIU: BFU2015-68354-P), T.H.S. was funded by the MCIU (PGC2018-095616-B-I00), the 2017 SGR 1089 (AGAUR), FEDER, the Centres of Excellence Severo Ochoa award and the CERCA Programme. M.S.-C. was supported by the IRB Barcelona. T.H.S, M.V-P, J.S. and U.S. were funded by the NIH Intramural Research Program, National Cancer Institute Center for Cancer Research. Sequencing and analysis were provided by the Broad Institute of MIT and Harvard Rare Genomes Project (RGP) and were funded by the National Human Genome Research Institute grants UM1 HG008900 (with additional support from the National Eye Institute, and the National Heart, Lung and Blood Institute), U01 HG0011755, and R01 HG009141 and in part by grant number 2020-224274 from the Chan Zuckerberg Initiative DAF, an advised fund of Silicon Valley Community Foundation. V.S.G. is supported by NIH NHGRI T32 (#1T32HG010464).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Mass General Brigham Institutional Review Board and informed consent was obtained from the participating family.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData are available in public, open access repositories GEO, ClinVar and PRIDE, included in the article or uploaded as supplemental material. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE241032 https://www.ncbi.nlm.nih.gov/clinvar/ https://www.ebi.ac.uk/pride/archive/projects/PXD019450